Review
Clevidipine (the Medicines Company)
Affiliations
- PMID: 12431021
Item in Clipboard
Review
Clevidipine (the Medicines Company)
Curr Opin Investig Drugs.
2002 Oct.
Abstract
The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II clinical evaluation by the original developer, AstraZeneca. By March 2002, The Medicines Company was conducting phase III clinical trials.
Similar articles
-
Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension.Ann Pharmacother. 2009 Jul;43(7):1258-65. doi: 10.1345/aph.1L610. Epub 2009 Jul 7. Ann Pharmacother. 2009. PMID: 19584385 Review.
-
Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension.Pharmacotherapy. 2010 May;30(5):515-28. doi: 10.1592/phco.30.5.515. Pharmacotherapy. 2010. PMID: 20412001 Review.
-
Clevidipine: a novel ultra-short-acting calcium antagonist.Cardiol Rev. 2009 May-Jun;17(3):147-52. doi: 10.1097/CRD.0b013e31819fe23c. Cardiol Rev. 2009. PMID: 19384089
-
Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for treatment of patients with acute severe hypertension answers to the march 2009 journal club questions.Ann Emerg Med. 2009 Aug;54(2):301-7. doi: 10.1016/j.annemergmed.2009.01.026. Ann Emerg Med. 2009. PMID: 19616729 No abstract available.
-
Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.Drug Metab Dispos. 1999 May;27(5):558-64. Drug Metab Dispos. 1999. PMID: 10220482
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical